Valuation
- Market cap
- 0
- Revenue TTM
- $0
- Net income TTM
- $-26,870,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 64,200
- Avg volume
- 16,682
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 50%
- Beta
- -0.09
- Analysts
- —
- Price target
- $3.00
Company profile
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the tre...
Show more
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 410 350 1839
- Website
- https://www.anthera.com
- Address
- The Pennzoil Building, Suite 1300 North Tower 700 Milam, Houston, United States
Latest news
No headlines yet.
